Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.

Inclusion Criteria: * Male of female, 18 years old or older. * Have been receiving chronic hemodialysis therapy * On stable EPO dosing regimen. * Have signed patient informed consent. * Predetermined serum ferritin and TSAT levels. * Clinical instability - inability to achieve adequate dialysis, abnormal serum albumin and serum glucose. * Pregnant or lactating. * A known sensitivity to Ferrlecit Exclusion Criteria: * Scheduled for renal transplant. * A serious concomitant medical disorders incompatible with participation in the study. * Unable to cooperate or comply with the protocol. * Use of any investigation agent within 30 days prior to study or during the course of the study. * Judged by the investigator as unsuitable for enrollment for any reason.